Clearmind Medicine Completes Second Cohort Enrollment for AUD Trial

Clearmind Medicine Inc. has successfully completed enrollment for the second cohort in its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD). The trial’s second cohort includes six patients and was rapidly recruited from three leading clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. This development comes on the heels of the first cohort’s completion, which reported promising safety and efficacy data.

The trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a proprietary MEAI-based compound designed to address AUD, a condition that affects millions globally. The swift recruitment of the second cohort underscores the operational excellence of the collaborating clinical sites, reflecting a strong commitment to advancing innovative treatments for AUD.

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, expressed enthusiasm regarding the accelerated pace of enrollment. “We are thrilled with the high level of interest from both patients and leading clinical sites in CMND-100’s potential to transform AUD treatment,” he stated. Building on the positive results from the first cohort, Dr. Zuloff-Shani highlighted that this rapid progress positions the company closer to generating valuable data that could lead to a breakthrough therapy addressing the root causes of addiction.

The multinational Phase I/IIa trial is designed to include a total of six patients in the second cohort, with dosing expected to commence shortly. Topline results are anticipated in the upcoming months, offering a clearer picture of CMND-100’s potential to deliver effective treatment options.

Clearmind Medicine is a clinical-stage biotech company dedicated to developing novel neuroplastogen-derived therapeutics for various under-treated health issues. The company holds a robust intellectual property portfolio comprising nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted. Shares of Clearmind are traded on Nasdaq under the symbol “CMND” and on the Frankfurt Stock Exchange under “CWY0.”

For more information, visit Clearmind’s official website or contact their Investor Relations team.

As Clearmind Medicine advances its clinical trials, the potential impact on AUD treatment remains significant. With millions of individuals affected by this disorder, innovative therapies like CMND-100 could transform the landscape of addiction treatment, highlighting the importance of ongoing research and development in this critical area of healthcare.